

**ASX Announcement**

**26 September 2024**

## **OncoSil Medical Achieves Key Milestones in TRIPP-FFX and PANCOSIL Clinical Trials: 50% Recruitment Completed in Both Studies**

### **Key Highlights**

- ✓ 50% of patient recruitment completed in the TRIPP-FFX clinical trial, with the 40<sup>th</sup> patient randomized.
- ✓ The PANCOSIL Investigator Initiated Trial reaches halfway mark with the 10<sup>th</sup> patient treated.

**Sydney, Australia – 26 September 2024:** Pancreatic cancer treatment device company **OncoSil Medical Limited (ASX:OSL)** (“OncoSil” or “the Company”) is pleased to announce two major milestones in its clinical trial programs.

In the TRIPP-FFX clinical trial, 50% of the target patient recruitment has now been completed, with the 40<sup>th</sup> patient randomized at The Christie NHS Foundation Trust in collaboration with Manchester University NHS Foundation Trust, UK. This clinical trial is important as it designed to assess the safety and efficacy of OncoSil™ when given in addition to standard FOLFIRINOX chemotherapy for treatment of Locally Advanced Pancreatic Cancer. The recruitment of the 40<sup>th</sup> patient marks a significant step forward in our efforts to bring this innovative treatment option to more patients worldwide.

Meanwhile, in the PANCOSIL Investigator Initiated Clinical Trial, conducted at Amsterdam UMC, the investigators have reached the halfway point of patient recruitment. The 10<sup>th</sup> patient has been successfully treated with the OncoSil™ device, marking another important milestone. This trial is evaluating the safety and feasibility of CT-guided percutaneous radionuclide therapy (RNT) using the OncoSil™ device in patients with non-progressive locally advanced pancreatic cancer. The trial aims to treat a total of 20 patients with the OncoSil™ device through percutaneous application.

OncoSil Medical CEO & Managing Director, Nigel Lange, commented: “We are thrilled to have reached these critical milestones in both the TRIPP-FFX and PANCOSIL trials. The dedication of our clinical partners is pivotal as we move closer to completing recruitment and advancing towards final data readouts. Reaching 50% recruitment in both trials is a testament to the potential of OncoSil™. We are excited to further validate the device's use in broader clinical applications.”

OncoSil Medical remains committed to providing regular updates as both trials progress towards completion and other key milestones are achieved.

## Authorisation & Additional Information

This announcement was authorised by the Board of Directors of OncoSil Medical Limited.

### For further information, please contact:

|  |  |   |
|--|--|---|
| <b>Mr. Nigel Lange</b><br>CEO & Managing Director<br>E: <a href="mailto:nigel.lange@oncosil.com">nigel.lange@oncosil.com</a><br>T: +49 30 300 149 3043 | <b>Mr. Christian Dal Cin</b><br>CFO & Company Secretary<br>E: <a href="mailto:c.dalcin@acclime.com">c.dalcin@acclime.com</a><br>T: +61 3 9824 5254 | <b>Ms. Julia Maguire</b><br><b>The Capital Network</b><br>Media and Investor Enquiries<br>E: <a href="mailto:julia@thecapitalnetwork.com.au">julia@thecapitalnetwork.com.au</a><br>T: +61 2 8999 3699 |
|--|--|---|

## About OncoSil Medical

OncoSil Medical Limited (ASX:OSL) has developed a cancer treatment device, the OncoSil™ brachytherapy device, which is a critical component of a revolutionary brachytherapy treatment for locally advanced unresectable pancreatic cancer. This type of cancer is the 12<sup>th</sup> most common cancer in men and the 11<sup>th</sup> most common cancer in women across the globe, with some 500,000 new cases of pancreatic cancer detected every year. With pancreatic cancer typically diagnosed at a later stage, it has a poor prognosis for long-term survival<sup>1</sup>.

The OncoSil™ device delivers a targeted intratumoural placement of Phosphorous-32 (<sup>32</sup>P) in the treatment of locally advanced unresectable pancreatic cancer. This occurs via injection directly into a patient's pancreatic tumours under endoscopic ultrasound guidance and takes place in combination with gemcitabine-based chemotherapy.

The OncoSil™ device that has already received breakthrough device designation in the European Union, United Kingdom and United States for the treatment of locally advanced unresectable pancreatic cancer in combination with chemotherapy. CE Marking has additionally been granted for the OncoSil™ device, which can be marketed in the European Union, United Kingdom.

While clinical trials involving the OncoSil™ device continue to occur, the Company is simultaneously moving to commercialise this unique medical technology. It is currently approved for sale in 30+ countries including European Union, United Kingdom, Türkiye and Israel, with initial commercial pancreatic cancer treatments using the device already undertaken in Spain, Italy and Israel.

To learn more, please visit: [www.oncosil.com/](http://www.oncosil.com/)

References: 1. [www.wcrf.org/cancer-trends/pancreatic-cancer-statistics](http://www.wcrf.org/cancer-trends/pancreatic-cancer-statistics)